<SEC-DOCUMENT>0001193125-26-259691.txt : 20260605
<SEC-HEADER>0001193125-26-259691.hdr.sgml : 20260605
<ACCEPTANCE-DATETIME>20260605163009
ACCESSION NUMBER:		0001193125-26-259691
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20260604
FILED AS OF DATE:		20260605
DATE AS OF CHANGE:		20260605

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Mulay James
		CENTRAL INDEX KEY:			0001684531
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41925
		FILM NUMBER:		261069564

	MAIL ADDRESS:	
		STREET 1:		C/O CG ONCOLOGY, INC.
		STREET 2:		400 SPECTRUM CENTER DRIVE, SUITE 2040
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92618

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CG Oncology, Inc.
		CENTRAL INDEX KEY:			0001991792
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				371611499
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		3000 PEGASUS PARK DRIVE
		STREET 2:		SUITE 1640
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75247
		BUSINESS PHONE:		(949) 409-3700

	MAIL ADDRESS:	
		STREET 1:		3000 PEGASUS PARK DRIVE
		STREET 2:		SUITE 1640
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75247
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>ownership.xml
<DESCRIPTION>4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0609</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2026-06-04</periodOfReport>

    <issuer>
        <issuerCik>0001991792</issuerCik>
        <issuerName>CG Oncology, Inc.</issuerName>
        <issuerTradingSymbol>CGON</issuerTradingSymbol>
        <issuerForeignTradingSymbol></issuerForeignTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001684531</rptOwnerCik>
            <rptOwnerName>Mulay James</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerNonUSAddressFlag>false</rptOwnerNonUSAddressFlag>
            <rptOwnerStreet1>C/O CG ONCOLOGY, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>3000 PEGASUS PARK DRIVE, SUITE 1640</rptOwnerStreet2>
            <rptOwnerCity>DALLAS</rptOwnerCity>
            <rptOwnerState>TX</rptOwnerState>
            <rptOwnerZipCode>75247</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
            <isOfficer>false</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>false</aff10b5One>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Director Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>56.09</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2026-06-04</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>9354</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2036-06-03</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>9354</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>9354</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Joshua F. Patterson, Attorney-in-Fact for James J. Mulay</signatureName>
        <signatureDate>2026-06-05</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
